Get the Stockscreener App
602.92
0.38%
2.26
Pre-market:
600.42
-2.50
-0.41%
Regeneron Pharmaceuticals Inc stock is traded at $602.92, with a volume of 1.08M.
It is up +0.38% in the last 24 hours and down -14.04% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$600.66
Open:
$596.52
24h Volume:
1.08M
Relative Volume:
1.33
Market Cap:
$63.21B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
14.69
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
-5.00%
1M Performance:
-14.04%
6M Performance:
-18.74%
1Y Performance:
+22.84%
1-Day Range:
$591.52
$604.63
1-Week Range:
$591.52
$638.06
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) And Encourages Shareholders to Connect - ACCESS Newswire
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pha - The National Law Review
Are Options Traders Betting on a Big Move in Regeneron Stock? - TradingView
Regeneron shares fall 12% since earnings despite strong Q1 beat - MSN
REGN Stock Price, Quote & Chart | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
Barclays initiates Regeneron stock with Overweight on Dupixent growth - Investing.com
Is Regeneron (REGN) Quietly Redefining Its Pipeline Focus With These Niche Therapy Advances? - simplywall.st
Regeneron develops Otarmeni, a surgically-delivered gene therapy drug - Lohud
(REGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised) - The Globe and Mail
Is Regeneron Pharmaceuticals Stock Underperforming the Dow? - Yahoo Finance
Regeneron Pharmaceuticals Inc stock (US7739031091): shares steady as EMA accepts eye drug filing and - AD HOC NEWS
13,565 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Eurizon Capital SGR S.p.A. - MarketBeat
Regeneron Cancer Drug Shows New Promise in a Rare Disease… and Maybe More - MedCity News
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein - The National Law Review
Norges Bank Invests $1.01 Billion in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application - Insider Monkey
WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus - simplywall.st
Regeneron Fell 15% Over the Past 30 Days. Here’s What to Expect in 2026 - TIKR.com
Big Biotech Leaders With Established Therapy Strength - Kalkine Media
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
2026-05-29 | Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharma 1Q Adj EPS $9.47 >REGN - Moomoo
Fideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Geode Capital Management LLC - MarketBeat
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment - GuruFocus
REGN News | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) And Encourages Investors to Connect - ACCESS Newswire
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials - GuruFocus
Regeneron Pharmaceuticals' Ebola Antibody Recommended by WHO for Investigational Use in Bundibugyo Ebolavirus - Moomoo
Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO - Seeking Alpha
WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak - Reuters
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak - The Manila Times
WHO prioritizes Regeneron Ebola antibody in Congo and Uganda outbreak trials - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Regeneron Has Fallen 22% Since May. Here’s What the TIKR Model Says About the Upside From Here - TIKR.com
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Notice to Long-Term Shareholders of Commvault Systems, Inc. - GlobeNewswire
Numerous Regeneron Pharmaceuticals Insiders Sold Stock: Not A Positive Omen - Moomoo
Allstate Corp Has $5.92 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
Regeneron to create hundreds of jobs with new Hyderabad GCC - HR Katha
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Low Can REGN Really Go In A Market Crash? - Trefis
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC - The Hindu
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event - Insider Monkey
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):